Dexcom (DXCM) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.62% |
| Dec 31, 2025 | 71.36% |
| Sep 30, 2025 | 86.78% |
| Jun 30, 2025 | 43.61% |
| Mar 31, 2025 | -5.16% |
| Dec 31, 2024 | -26.35% |
| Sep 30, 2024 | 20.20% |
| Jun 30, 2024 | 21.64% |
| Mar 31, 2024 | -10.64% |
| Dec 31, 2023 | 68.11% |
| Sep 30, 2023 | -110.19% |
| Jun 30, 2023 | -28.30% |
| Mar 31, 2023 | -64.71% |
| Dec 31, 2022 | -181.40% |
| Sep 30, 2022 | 52.56% |
| Jun 30, 2022 | -11.18% |
| Mar 31, 2022 | -80.66% |
| Dec 31, 2021 | -95.66% |
| Sep 30, 2021 | 29.41% |
| Jun 30, 2021 | 108.95% |
| Mar 31, 2021 | -58.55% |
| Dec 31, 2020 | -13.57% |
| Sep 30, 2020 | -10.29% |
| Jun 30, 2020 | -174.16% |
| Mar 31, 2020 | 47.76% |
| Dec 31, 2019 | -82.17% |
| Sep 30, 2019 | -155.38% |
| Jun 30, 2019 | -175.89% |
| Mar 31, 2019 | 100.66% |
| Dec 31, 2018 | 128.14% |
| Sep 30, 2018 | 22.03% |
| Jun 30, 2018 | -95.02% |
| Mar 31, 2018 | -26.37% |
| Dec 31, 2017 | -16.72% |
| Sep 30, 2017 | -65.61% |
| Jun 30, 2017 | -71.70% |
| Mar 31, 2017 | -30.80% |
| Dec 31, 2016 | -37.85% |
| Sep 30, 2016 | -10.92% |
| Jun 30, 2016 | 24.49% |
| Mar 31, 2016 | -29.58% |
| Dec 31, 2015 | 9.06% |
| Sep 30, 2015 | -22.67% |